Journal of Cancer Therapy

Journal of Cancer Therapy

ISSN Print: 2151-1934
ISSN Online: 2151-1942
www.scirp.org/journal/jct
E-mail: jct@scirp.org
"Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium"
written by Cody P. Coyne, Toni Jones, Andrzej Sygula, John Bailey, Lesya Pinchuk,
published by Journal of Cancer Therapy, Vol.2 No.1, 2011
has been cited by the following article(s):
  • Google Scholar
  • CrossRef
[1] Carnosic Acid, Tangeretin, and Ginkgolide-B Anti-neoplastic Cytotoxicity in Dual Combination with Dexamethasone-[anti-EGFR] in Pulmonary Adenocarcinoma (A549 …
2019
[2] Mebendazole in simultaneous combination with dexamethasone- (C21-phosphoramidate)-[anti-EGFR] generated utilizing a novel synthesis regimen: dual anti …
2019
[3] Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties …
Current Pharmaceutical Design, 2018
[4] Anti-neoplastic cytotoxicity by complementary simultaneous selective “targeted” delivery for pulmonary adenocarcinoma: fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] in dual …
Journal of Pharmaceutical Investigation, 2018
[5] Gemcitabine‐(5′‐phosphoramidate)‐[anti‐IGF‐1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of …
Chemical biology & drug design, 2017
[6] Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against …
Drug design, development and therapy, 2016
[7] Gemcitabine‐(5'‐phosphoramidate)‐[anti‐IGF‐1R]: Molecular Design, Synthetic Organic Chemistry Reactions, and Antineoplastic Cytotoxic Potency in Populations of …
Chemical biology & drug design, 2016
[8] Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against …
Drug design, development and therapy, 2016
[9] Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se] …
Journal of cancer therapy, 2015
[10] Fludarabine-(C2-methylhydroxyphosphoramide)-[anti-IGF-1R]: synthesis and selectively “targeted” anti-neoplastic cytotoxicity against pulmonary …
Journal of pharmaceutics & drug delivery research, 2015
[11] Fludarabine-(C2-methylhydroxyphosphoramide)-[anti-IGF-1R]: Synthesis and Selectively “Targeted” Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549)
Journal of pharmaceutics & drug delivery research, 2015
[12] Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se] …
Journal of cancer therapy, 2015
[13] Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine
Journal of Cancer Therapy, 2014
[14] Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole
Journal of cancer research and therapeutic oncology, 2014
[15] Anti-neoplastic cytotoxicity of gemcitabine-(C4-amide)-[anti-EGFR] in dual-combination with epirubicin-(C3-amide)-[anti-HER2/neu] against chemotherapeutic …
Medicinal chemistry, 2014
[16] Gemcitabine-(C4-amide)-[anti-HER2/neu] anti-neoplastic cytotoxicity in dual combination with mebendazole against chemotherapeutic-resistant mammary …
Journal of clinical & experimental oncology, 2013
[17] Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary …
Journal of clinical & experimental oncology, 2013
[18] Anti-neoplastic cytotoxicity of gemcitabine-(C4-amide)-[anti-HER2/neu] in combination with Griseofulvin against chemotherapeutic-resistant mammary …
Medicinal chemistry, 2013
[19] Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma
Journal of Clinical & Experimental Oncology, 2013
[20] Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3)
Medicinal Chemistry, 2013
[21] Anti-neoplastic cytotoxicity of gemcitabine-(C4-amide)-[anti-HER2/neu] in combination with griseofulvin against chemotherapeutic-resistant mammary …
Medicinal chemistry, 2013
[22] Synthesis of a Covalent Epirubicin-(C3-amide)-Anti-HER2/neu Immunochemotherapeutic Utilizing a UV-Photoactivated Anthracycline Intermediate
Cancer Biotherapy and Radiopharmaceuticals?, 2012
[23] Synthesis of Gemcitabine-(C 4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3
Journal of Cancer Therapy, 2012
[24] Influence of Alternative Tubulin Inhibitors on the Potency of Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate
Cancer and Clinical Oncology, 2012
[25] Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic Anti-Neoplastic Potency of Epirubicin-(C3-amide)-Anti-HER2/neu Synthesized Utilizing a UV-Photoactivated Anthracycline Intermediate
Cancer and clinical oncology, 2012
[26] Synthesis of gemcitabine-(C4-amide)-[anti-HER2/neu] utilizing a UV-photoactivated gemcitabine intermediate: cytotoxic anti-Neoplastic activity against …
Journal of cancer therapy, 2012
[27] Synthesis of gemcitabine-(C4-amide)-[anti-HER2/neu] utilizing a UV-photoactivated gemcitabine intermediate: cytotoxic anti-Neoplastic activity against …
Journal of cancer therapy, 2012
[28] Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated …
Cancer and Clinical Oncology, 2012
Free SCIRP Newsletters
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top